ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36775
0.00%
Bitcoin
61,149.30
0.58%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BioLineRx Ltd (BLRX)

  7. BioLineRx Ltd (BLRX) News

BLRX

BioLineRx (BLRX)

BioLineRx Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BLRX
DateTimeSourceHeadlineSymbolCompany
05/06/20246:14AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
04/17/20246:00AMPR Newswire (US)BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingNASDAQ:BLRXBioLineRx Ltd
03/04/20246:47AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
02/28/20246:08AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
02/16/20246:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
01/07/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BLRXBioLineRx Ltd
12/29/20233:20PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLRXBioLineRx Ltd
12/29/20233:15PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BLRXBioLineRx Ltd
12/21/20236:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
12/12/20236:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
11/20/20236:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
11/20/20235:25AMIH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:BLRXBioLineRx Ltd
11/01/20236:43AMPR Newswire (Canada)BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
10/31/20238:00AMPR Newswire (US)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
10/31/20238:00AMPR Newswire (Canada)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
10/26/20231:18PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BLRXBioLineRx Ltd
10/18/20234:07PMAllPennyStocks.comNew Collaboration Could Revolutionize Treatment of Chronic Spinal Cord InjuriesNASDAQ:BLRXBioLineRx Ltd
10/12/20236:14AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
09/28/20236:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
09/11/20236:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
09/11/20236:00AMPR Newswire (US)BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaNASDAQ:BLRXBioLineRx Ltd
08/30/20236:16AMIH Market NewsWednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and moreNASDAQ:BLRXBioLineRx Ltd
08/30/20236:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
08/30/20235:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
08/08/20234:25PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
07/17/20236:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
06/23/20233:17PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
05/24/20236:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
04/25/20236:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
04/17/202310:09AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
 Showing the most relevant articles for your search:NASDAQ:BLRX

Your Recent History

DOWI
DWCIOF
DJ US Industrial and Off...
LSE
ZOO
Zoo Digital
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved